Scholars Central

Conference abstractPublished 22 Oct 2012

Anti-CD52 therapy in multiple sclerosis

Authors: Michael J. Turner

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Alemtuzumab is a humanized monoclonal antibody that selectively targets CD52 to deplete circulating T and B lymphocytes, thought to be critical mediators of MS inflammatory processes. Alemtuzumab has minimal impact on other immune cells. A distinctive pattern of T and B cell repopulation begins within weeks, potentially leading to a rebalancing of the immune system. Although alemtuzumab�s exact mechanism of action is unknown, these pharmacodynamic changes may help explain its effect in MS Preclinical studies have focused on using a murine CD52 specific antibody to expand our understanding of anti-CD52 therapy in the C57BL/6 model of experimental autoimmune encephalomyelitis. These studies have demonstrated a profound impact of anti-muCD52 therapy on the course of disease. Specifically, therapeutic intervention inhibited disease development in animals prior to observable symptoms and reversed existing paralytic symptoms in more severely disabled animals. Longitudinal flow cytometric evaluation demonstrated a decrease in the number of lymphocytes in the CNS as well as circulating autoreactive T cells. Histological evaluation also showed a reduction in the level of lymphocytic infiltrate in the CNS of anti-muCD52 treated animals. Collectively, these results demonstrate the therapeutic efficacy of anti-muCD52 treatment in a murine model of EAE.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Clinical and Cellular Immunology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Michael J. Turner”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels